BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 31852152)

  • 1. Effectiveness of 23-valent pneumococcal polysaccharide vaccine on elderly patients with colorectal cancer: A population-based propensity score-matched cohort study.
    Chiou WY; Hung SK; Lin HY; Chen LC; Hsu FC; Tsai SJ; Yu BH; Lee MS; Li CY
    Medicine (Baltimore); 2019 Dec; 98(50):e18380. PubMed ID: 31852152
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of 23-valent pneumococcal polysaccharide vaccine on elderly long-term cancer survivors: a population-based propensity score matched cohort study.
    Chiou WY; Lee MS; Hung SK; Lin HY; Lo YC; Hsu FC; Tsai SJ; Li CY
    BMJ Open; 2018 May; 8(5):e019364. PubMed ID: 29769253
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of 23-Valent Pneumococcal Polysaccharide Vaccine Inoculated During Anti-Cancer Treatment Period in Elderly Lung Cancer Patients on Community-Acquired Pneumonia Hospitalization: A Nationwide Population-Based Cohort Study.
    Chiou WY; Hung SK; Lai CL; Lin HY; Su YC; Chen YC; Shen BJ; Chen LC; Tsai SJ; Lee MS; Li CY
    Medicine (Baltimore); 2015 Jul; 94(26):e1022. PubMed ID: 26131806
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of 23-valent pneumococcal polysaccharide vaccination on the frequency of pneumonia-related hospitalization and survival in elderly patients with prostate cancer: A seven-year nationwide matched cohort study.
    Li CY; Chen LC; Lin HY; Lee MS; Hung SK; Lai CL; Huang LW; Yu BH; Hsu FC; Chiou WY
    Cancer; 2021 Jan; 127(1):124-136. PubMed ID: 32997342
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Effectiveness of 23-valent Pneumococcal Polysaccharide Vaccine on Elderly Colorectal Cancer Long-Term Survivors: A population-based exact-matched cohort study.
    Lee MS; Chiou SY; Hsu FC; Lin HY; Li CY; Hung SK; Yu BH; Wu CC; Chen LC; Chew CH; Chiou WY
    Hum Vaccin Immunother; 2024 Dec; 20(1):2350093. PubMed ID: 38744302
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical effectiveness of 13-valent and 23-valent pneumococcal vaccination in middle-aged and older adults: The EPIVAC cohort study, 2015-2016.
    Vila-Corcoles A; Hospital I; Ochoa-Gondar O; Satue E; de Diego C; Vila-Rovira A; Gómez-Bertomeu F; Raga X; Aragón M
    Vaccine; 2020 Jan; 38(5):1170-1180. PubMed ID: 31759735
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 23-valent pneumococcal polysaccharide vaccine improves survival in dialysis patients by preventing cardiac events.
    Ihara H; Kikuchi K; Taniguchi H; Fujita S; Tsuruta Y; Kato M; Mitsuishi Y; Tajima K; Kodama Y; Takahashi F; Takahashi K; Azuma N
    Vaccine; 2019 Oct; 37(43):6447-6453. PubMed ID: 31526624
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preventive effects of pneumococcal and influenza vaccines on community-acquired pneumonia in older individuals in Japan: a case-control study.
    Suzuki K; Kondo K; Washio M; Nakashima K; Kan S; Imai S; Yoshimura K; Ota C; Ohfuji S; Fukushima W; Hirota Y
    Hum Vaccin Immunother; 2019; 15(9):2171-2177. PubMed ID: 30785356
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness of 23-valent pneumococcal polysaccharide vaccine and seasonal influenza vaccine for pneumonia among the elderly - Selection of controls in a case-control study.
    Kondo K; Suzuki K; Washio M; Ohfuji S; Fukushima W; Maeda A; Hirota Y;
    Vaccine; 2017 Aug; 35(36):4806-4810. PubMed ID: 28818473
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness of 23-valent pneumococcal polysaccharide vaccine against invasive disease and hospital-treated pneumonia among people aged ≥65 years: a retrospective case-control study.
    Leventer-Roberts M; Feldman BS; Brufman I; Cohen-Stavi CJ; Hoshen M; Balicer RD
    Clin Infect Dis; 2015 May; 60(10):1472-80. PubMed ID: 25669354
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of initial vaccination with 13-valent pneumococcal conjugate vaccine or 23-valent pneumococcal polysaccharide vaccine on anti-pneumococcal responses following subsequent pneumococcal vaccination in adults 50 years and older.
    Jackson LA; Gurtman A; van Cleeff M; Frenck RW; Treanor J; Jansen KU; Scott DA; Emini EA; Gruber WC; Schmoele-Thoma B
    Vaccine; 2013 Aug; 31(35):3594-602. PubMed ID: 23688525
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The 23-valent pneumococcal polysaccharide vaccine is effective in elderly adults over 75 years old--Taiwan's PPV vaccination program.
    Tsai YH; Hsieh MJ; Chang CJ; Wen YW; Hu HC; Chao YN; Huang YC; Yang CT; Huang CC
    Vaccine; 2015 Jun; 33(25):2897-902. PubMed ID: 25936662
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pneumococcal and influenza vaccination status of hospitalized adults with community acquired pneumonia and the effects of vaccination on clinical presentation.
    Demirdogen Cetinoglu E; Uzaslan E; Sayıner A; Cilli A; Kılınc O; Sakar Coskun A; Hazar A; Kokturk N; Filiz A; Polatli M;
    Hum Vaccin Immunother; 2017 Sep; 13(9):2072-2077. PubMed ID: 28708954
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluating clinical effectiveness and impact of anti-pneumococcal vaccination in adults after universal childhood PCV13 implementation in Catalonia, 2017-2018.
    Vila-Córcoles A; Ochoa-Gondar O; de Diego-Cabanes C; Satué-Gracia EM; Torras-Vives V; Forcadell-Peris MJ; Ribas-Seguí D; Vila-Rovira A; Rodríguez-Casado C
    Vaccine X; 2023 Apr; 13():100264. PubMed ID: 36798107
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine.
    Jackson LA; Gurtman A; Rice K; Pauksens K; Greenberg RN; Jones TR; Scott DA; Emini EA; Gruber WC; Schmoele-Thoma B
    Vaccine; 2013 Aug; 31(35):3585-93. PubMed ID: 23688527
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of a 23-valent pneumococcal polysaccharide vaccine for the prevention of pneumococcal pneumonia in the elderly with chronic respiratory diseases: a case-control study of a single center.
    Masuda T; Nakatani E; Shirai T; Akamatsu T; Tamura K; Takahashi S; Tanaka Y; Watanabe H; Endo Y; Suzuki T; Saigusa M; Yamamoto A; Morita S; Sato Y; Asada K
    BMC Pulm Med; 2021 Apr; 21(1):123. PubMed ID: 33863300
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of sequential vs single pneumococcal vaccination on cardiovascular diseases among older adults: a population-based cohort study.
    Tong X; Gao L; Wong ICK; Chan VKY; Wong AYS; Mak JCW; Yuen JKY; Jit M; Hung IFN; Yiu KH; Li X
    Int J Epidemiol; 2024 Feb; 53(1):. PubMed ID: 38332579
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of influenza and pneumococcal vaccines on chronic obstructive pulmonary disease exacerbations.
    Li Y; Zhang P; An Z; Yue C; Wang Y; Liu Y; Yuan X; Ma Y; Li K; Yin Z; Wang L; Wang H
    Respirology; 2022 Oct; 27(10):844-853. PubMed ID: 35705329
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of the 23-valent pneumococcal polysaccharide vaccine on the incidence of hospitalization with pneumonia in adults aged ≥65 years: retrospective cohort study using a population-based database in Japan.
    Yamana H; Ono S; Michihata N; Uemura K; Jo T; Yasunaga H
    Clin Microbiol Infect; 2023 Jul; 29(7):904-910. PubMed ID: 37044276
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association between regular physical activity and pneumonia-related hospitalization according to pneumococcal vaccination status: The VENUS study.
    Murata F; Maeda M; Ono R; Fukuda H
    Vaccine; 2024 Feb; 42(6):1268-1274. PubMed ID: 38281899
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.